FISHER v. FENNEC PHARMACEUTICALS INC.

CourtDistrict Court, M.D. North Carolina
DecidedMay 9, 2022
Docket1:22-cv-00115
StatusUnknown

This text of FISHER v. FENNEC PHARMACEUTICALS INC. (FISHER v. FENNEC PHARMACEUTICALS INC.) is published on Counsel Stack Legal Research, covering District Court, M.D. North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
FISHER v. FENNEC PHARMACEUTICALS INC., (M.D.N.C. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF NORTH CAROLINA

JEFFREY D. FISHER, Individually ) and on behalf of all others similarly ) situated, ) ) Plaintiff, ) ) v. ) 1:22-CV-115 ) FENNEC PHARMACEUTICALS ) INC., ROSTISLAV RAYKOV, and ) ROBERT ANDRADE, ) ) Defendants. )

MEMORANDUM OPINION AND ORDER Catherine C. Eagles, District Judge. Plaintiff Jeffrey Fisher filed this securities class action lawsuit alleging Fennec Pharmaceuticals Inc., Rostislav Raykov, and Robert Andrade violated §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 and related regulations. Mr. Fisher seeks appointment as lead plaintiff and approval of Pomerantz LLP as lead counsel and Schiller & Schiller, PLLC as liaison counsel for the putative class. The defendants take no position on the motion. Because all requirements have been met and there is no evidence suggesting either Mr. Fisher or his selected counsel will not adequately handle this matter, the Court will appoint Mr. Fisher as lead plaintiff and approve his selection of lead and liaison counsel. I. Appointment of Lead Plaintiff The Private Securities Litigation Reform Act of 1995 governs securities class actions and imposes procedural requirements for the appointment of lead plaintiff. See

15 U.S.C. § 78u-4(a)(3). Under the statute, the Court must appoint as lead plaintiff the plaintiff whom the Court determines to be “most capable of adequately representing the interests of class members . . . in accordance with” a number of provisions. § 78u- 4(a)(3)(B)(i). Among these are certain notice requirements, § 78u-4(a)(3)(A), and a presumption in favor of a plaintiff who satisfies those requirements, has the largest

financial interest in the relief sought by the class, and satisfies the requirements of Federal Rule of Civil Procedure 23. § 78u-4(a)(3)(B)(iii)(I). The Court finds the following: 1. The PSLRA requires that, within 20 days after filing suit, a plaintiff must publish a notice advising potential class members “of the pendency of the

action, the claims asserted therein, and the purported class period.” § 78u- 4(a)(3)(A)(i). 2. Mr. Fisher filed suit on February 9, 2022. The same day, Mr. Fisher’s counsel published a notice via GlobeNewsWire informing class members of their right to file motions for appointment as lead plaintiff, Doc. 16 at 10, Doc. 13-1 at 2–

3, satisfying the requirement of § 78u-4(a)(3)(A)(i). See Simmons v. Spencer, No. 13-CV-8216, 2014 WL 1678987, at *2–3 (S.D.N.Y. Apr. 25, 2014) (stating that GlobeNewsWire is “a widely circulated national business-oriented publication or wire service” for § 78u–4(a)(3)(A)(i)'s purposes). 3. The PSLRA allows any member of the putative class to file a motion to serve as lead plaintiff no later than 60 days after the notice is published. § 78u- 4(a)(3)(A)(i)(II).

4. On April 11, 2022, 60 days after notice was published, Mr. Fisher filed this motion to serve as lead plaintiff. Doc. 15. 5. The PSLRA provides that not more than 90 days after notice is published, the court will consider the pending motions and appoint a lead plaintiff it “determines to be most capable of adequately representing the interests of class

members.” § 78u-4(a)(3)(B)(i). 6. Not more than 90 days have passed since the notice was published. 7. In determining if Mr. Fisher is most capable of leading the class, the Court must presume that the most adequate plaintiff is the person who (a) has filed the complaint or made a motion in response to the notice; (b) has the largest

financial interest in the relief sought by the class; and (c) otherwise satisfies the requirements of Fed. R. Civ. P. 23. § 78u-4(a)(3)(B)(iii)(I). 8. As to the first requirement, Mr. Fisher filed the complaint and timely moved to serve as lead plaintiff. 9. As to the second requirement, Mr. Fisher purchased 1,050 shares of Fennec

securities, expended $10,406 on his purchases of Fennec securities, retained 1,050 of his shares of Fennec securities, and suffered losses of $5,635 in Fennec securities during the class period. See Doc. 16 at 11; Doc. 16-1. There is no evidence anyone has a larger financial interest in the relief sought. 10. As to the third requirement, “[a] presumptive lead plaintiff need make only a prima facie showing that it can satisfy the typicality and adequacy requirements of Rule 23 to be appointed.” In re Cree, Inc., Sec. Litig., 219

F.R.D. 369, 372 (M.D.N.C. 2003). “The typicality requirement of the rule requires that a lead plaintiff suffer the same injuries as the class as a result of the defendant’s conduct and has claims based on the same legal issues.” Id. “Adequate representation requires a finding that the purported class representative and its attorney are capable of pursuing the litigation and that

neither has a conflict of interest with other class members.” Id. (citing Sosna v. Iowa, 419 U.S. 393, 403 (1975)). 11. As to typicality, Mr. Fisher purchased Fennec securities during the class period, see Doc. 16-1 at 2, and he claims he did so based on the same allegedly misleading statements and omission of material facts the complaint highlights.

See Doc. 16 at 12–13. 12. As to adequacy, Mr. Fisher and his attorneys are willing and able to pursue the litigation. Id. at 13–14. Mr. Fisher has certified that he is willing to participate in this litigation and will represent the class’s interests actively and zealously. See generally Doc. 16-5. The Court is unaware of any conflicts of interest or

antagonism between Mr. Fisher and the rest of the class. As discussed below, the group has retained experienced, able counsel. 13. Once the requirements for the presumption of most adequate lead plaintiff are met, the presumption may be rebutted only upon proof by a class member that the presumptively most adequate plaintiff “will not fairly and adequately protect the interests of the class” or “is subject to unique defenses that render such plaintiff incapable of adequately representing the class.” § 78u-

4(a)(3)(B)(iii)(II). 14. The Court is aware of no evidence that might rebut the presumption raised by the foregoing. Because Mr. Fisher satisfies the above requirements, the Court will appoint him as lead plaintiff.

II. Appointment of Lead Counsel Under the PSLRA, “[t]he most adequate plaintiff shall, subject to the approval of the court, select and retain counsel to represent the class.” § 78u-4(a)(3)(B)(v). “Although deference should be given to the lead plaintiff’s selection of counsel, approval of lead counsel is a matter within the court’s discretion.” Vaitkuviene v. Syneos Health,

Inc., 18-CV-29, 2018 WL 3460409, at *2 (E.D.N.C. May 29, 2018). In determining whether to approve movant’s selection of lead counsel, the Court considers the quality and cost of counsel, the “work counsel has done in identifying or investigating potential claims in the actions, counsel’s experience in handling class actions and other complex litigation and claims of the types asserted in the present action, counsel’s knowledge of

the applicable law, and the resources counsel will commit to representing the class.” In re Cree, Inc., 219 F.R.D. at 373; see also Fed. R. Civ. P. 23(g). The Court finds the following: 1. Mr. Fisher has selected Pomerantz LLP as lead counsel and Schiller & Schiller, PLLC as liaison counsel. Doc. 15. 2. Both firms appear experienced in the area of securities actions and class action

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sosna v. Iowa
419 U.S. 393 (Supreme Court, 1975)
In re Cree, Inc., Securities Litigation
219 F.R.D. 369 (M.D. North Carolina, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
FISHER v. FENNEC PHARMACEUTICALS INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/fisher-v-fennec-pharmaceuticals-inc-ncmd-2022.